Clonal replacement of tumor-specific T cells following PD-1 blockade

Nature Medicine, Год журнала: 2019, Номер 25(8), С. 1251 - 1259

Опубликована: Июль 29, 2019

Язык: Английский

---

CD8+ T cell states in human cancer: insights from single-cell analysis

Nature reviews. Cancer, Год журнала: 2020, Номер 20(4), С. 218 - 232

Опубликована: Фев. 5, 2020

Язык: Английский

---

Dysfunctional CD8 T Cells Form a Proliferative, Dynamically Regulated Compartment within Human Melanoma

Cell, Год журнала: 2018, Номер 176(4), С. 775 - 789.e18

Опубликована: Дек. 27, 2018

Язык: Английский

---

Advances in the development of personalized neoantigen-based therapeutic cancer vaccines

Nature Reviews Clinical Oncology, Год журнала: 2021, Номер 18(4), С. 215 - 229

Опубликована: Янв. 20, 2021

Язык: Английский

---

CD8+ T cell differentiation and dysfunction in cancer

Nature reviews. Immunology, Год журнала: 2021, Номер 22(4), С. 209 - 223

Опубликована: Июль 12, 2021

Язык: Английский

---

Tumor-infiltrating lymphocytes in the immunotherapy era

Cellular and Molecular Immunology, Год журнала: 2020, Номер 18(4), С. 842 - 859

Опубликована: Ноя. 2, 2020

Язык: Английский

---

Intratumoral CD4+ T Cells Mediate Anti-tumor Cytotoxicity in Human Bladder Cancer

Cell, Год журнала: 2020, Номер 181(7), С. 1612 - 1625.e13

Опубликована: Июнь 1, 2020

Responses to anti-PD-1 immunotherapy occur but are infrequent in bladder cancer. The specific T cells that mediate tumor rejection unknown. from human tumors and non-malignant tissue were assessed with single-cell RNA paired cell receptor (TCR) sequencing of 30,604 7 patients. We find the states repertoires CD8+ not distinct compared tissues. In contrast, analysis CD4+ demonstrates several tumor-specific states, including multiple regulatory cells. Surprisingly, we also cytotoxic clonally expanded. These can kill autologous an MHC class II-dependent fashion suppressed by Further, a gene signature predicts clinical response 244 metastatic cancer patients treated anti-PD-L1.

Язык: Английский

---

A single-cell map of intratumoral changes during anti-PD1 treatment of patients with breast cancer

Nature Medicine, Год журнала: 2021, Номер 27(5), С. 820 - 832

Опубликована: Май 1, 2021

Язык: Английский

---

Clinical implications of T cell exhaustion for cancer immunotherapy

Nature Reviews Clinical Oncology, Год журнала: 2022, Номер 19(12), С. 775 - 790

Опубликована: Окт. 10, 2022

Язык: Английский

---

Single-cell analyses reveal key immune cell subsets associated with response to PD-L1 blockade in triple-negative breast cancer

Cancer Cell, Год журнала: 2021, Номер 39(12), С. 1578 - 1593.e8

Опубликована: Окт. 16, 2021

In triple-negative breast cancer (TNBC), the benefit of combining chemotherapy with checkpoint inhibitors is still not very clear. We utilize single-cell RNA- and ATAC-sequencing to examine immune cell dynamics in 22 patients advanced TNBC treated paclitaxel or its combination anti-PD-L1 atezolizumab. demonstrate that high levels baseline CXCL13+ T cells are linked proinflammatory features macrophages can predict effective responses therapy. responsive patients, lymphoid tissue inducer (LTi) cells, follicular B (Bfoc) conventional type 1 dendritic (cDC1) concertedly increase following therapy, but instead decrease after monotherapy. Our data highlight importance therapies suggest their reduction by regimen may compromise clinical outcomes accompanying atezolizumab for treatment.

Язык: Английский

---